Hostname: page-component-5db58dd55d-mhzq2 Total loading time: 0 Render date: 2026-05-26T06:46:44.576Z Has data issue: false hasContentIssue false
  • English
  • Français

Reviewer Comment on Momen et al. “Demographic and Clinical Characteristics of Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder in Canadian Adults”

Published online by Cambridge University Press:  26 May 2026

Jodie M. Burton Open the ORCID record for Jodie M. Burton [Opens in a new window]
Jodie M. Burton*
Affiliation:
Departments of Clinical Neurosciences and Community Health Sciences, University of Calgary Cumming School of Medicine , Canada
*
Email: jodie.burton@albertahealthservices.ca
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Reviewer Comment
Information
Canadian Journal of Neurological Sciences , First View , pp. 1
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Hor, JY, Asgari, N, Nakashima, I, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol. 2020;11:501. doi: 10.3389/fneur.2020.00501.CrossRefGoogle ScholarPubMed
Osborne, B, Bernitsas, E, Rebeira, M, et al. The total economic impact of anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) on patients and caregivers in the United States (P7-8.008). Neurology. 2025;104:1746. doi: 10.1212/WNL.0000000000208721.CrossRefGoogle Scholar
Momen, A, Freedman, M, Fadda, G, et al. Demographic and clinical characteristics of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder in Canadian adults. Can J Neurosci. 2026.Google ScholarPubMed
Holian, AH, Weinshenker, BG. Emerging role of targeted monoclonal antibodies in neuromyelitis optica spectrum disorders. BioDrugs. 2025;39:573–89. doi: 10.1007/s40259-025-00729-x.CrossRefGoogle ScholarPubMed
Carlson, AM, Sollero, CEV, Wolf, AB, et al. The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population. Ann Clin Transl Neurol. 2025;12(1):169–79. doi: 10.1002/acn3.52268.CrossRefGoogle Scholar
Briggs, FB, Shaia, J. Prevalence of neuromyelitis optica spectrum disorder in the United States. Mult Scler J. 2024;30(3):316–24. doi: 10.1177/13524585231224683.CrossRefGoogle Scholar